Capricor Therapeutics has announced that it is stopping progress on a trial for a new Duchenne muscular dystrophy (DMD) treatment.
According to the company, one of the study’s patients had a severe allergic reaction to the medication under review. The patient fully recovered, but Capricor is now working with the FDA on a mitigation plan to continue the study.
There is no cure for DMD, which impacts about 200,000 new patients in the U.S. each year. The condition is marked by progressive muscle weakness and learning disabilities.
An earlier trial demonstrated that Capricor’s new drug, CAP-1002, could significantly improve patients’ cardiac and skeletal muscle function.
Read the full Reuters report.